In today’s recent session, 2.37 million shares of the Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) have been traded, and its beta is 0.61. Most recently the company’s share price was $17.59, and it changed around $0.6 or 3.51% from the last close, which brings the market valuation of the company to $20.17B. TEVA at last check was trading at a discount to its 52-week high of $22.80, offering almost -29.62% off that amount. The share price’s 52-week low was $12.47, which indicates that the recent value has risen by an impressive 29.11% since then.
Teva- Pharmaceutical Industries Ltd. ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.40. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended TEVA as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
Instantly TEVA has been showing a green trend so far today with a performance of 3.51% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 18.28 on recent trading dayincreased the stock’s daily price by 3.77%. The company’s shares are currently down -20.21% year-to-date, but still down -2.68% over the last five days. On the other hand, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) is 4.24% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $28, which translates to bulls needing to increase their stock price by 37.18% from its current value. Analyst projections state that TEVA is forecast to be at a low of $28 and a high of $28.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -9.62%. Teva- Pharmaceutical Industries Ltd. ADR earnings are expected to increase by 1.95% in 2025, but the outlook is positive 7.35% per year for the next five years.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR’s next quarterly earnings report is expected to be released in July.
FMR LLC, with 3.7051% or 41.98 million shares worth $682.15 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
